Question

Difficulty: Very hardMenstrual Cycle Abnormalities and Contraception

An 18-year-old woman is brought to the clinic by her mother due to the absence of spontaneous menarche. The patient states she has never had menstrual bleeding or spotting. She is a high school senior and performs well academically, though she notes a lifelong inability to smell her mother's cooking or her own perfume. She denies headaches, visual changes, or galactorrhea. She takes no medications and does not use illicit substances. Vital signs include a blood pressure of 110/70 mm Hg, heart rate of 72/min, respiratory rate of 14/min, and BMI of 21 kg/m^2. Physical examination reveals Tanner stage 1 breast development and Tanner stage 2 pubic hair. External genitalia appear normal and there is no clitoromegaly. Based on the standard diagnostic and management algorithm for primary amenorrhea, arrange the following clinical steps in the most appropriate sequential order for this patient.

  1. 1Performance of a quantitative serum or urine beta-hCG test
  2. 2Pelvic ultrasonography to evaluate internal reproductive organs
  3. 3Measurement of serum follicle-stimulating hormone (FSH) and luteinizing hormone (LH)
  4. 4Magnetic resonance imaging (MRI) of the brain and olfactory tracts
  5. 5Initiation of cyclical estrogen and progestin therapy

Answer

The correct sequence of steps is: Performance of a beta-hCG test, followed by pelvic ultrasonography, followed by measurement of serum FSH and LH, followed by MRI of the brain, and finally initiation of cyclical estrogen and progestin therapy.
The evaluation of primary amenorrhea follows a rigid step-wise algorithm. Regardless of the patient's age or Tanner stage, a pregnancy test is the mandatory initial step. Once pregnancy is excluded, pelvic ultrasonography is performed to determine if a uterus is present. In a patient with a uterus but absent breast development, serum FSH is measured next to distinguish between primary ovarian insufficiency (hypergonadotropic) and central defects (hypogonadotropic). Since this patient's anosmia suggests Kallmann syndrome (a hypogonadotropic state), her FSH would be low. This biochemical finding mandates a brain MRI to evaluate for olfactory bulb agenesis and rule out intracranial tumors. Finally, once the diagnosis is secured, cyclical estrogen and progestin therapy is initiated to promote pubertal development and bone health.

Step-by-Step Solution

1
Exclude pregnancy via beta-hCG testing.
Beta-hCG level is obtained.
Pregnancy is the most common cause of amenorrhea and must universally be ruled out first, even in patients who appear prepubertal or deny sexual activity.
2
Determine the anatomical presence of Müllerian structures via pelvic ultrasound.
Confirmation of the presence or absence of a uterus.
The diagnostic algorithm for primary amenorrhea diverges heavily based on anatomy. An absent uterus prompts karyotype and testosterone testing, while a present uterus prompts pituitary/ovarian axis testing.
3
Localize the hormonal defect via serum FSH and LH measurement.
Differentiation between central and peripheral causes.
Given the lack of breast development, estrogen is low. FSH determines if this is due to ovarian failure (high FSH) or a hypothalamic/pituitary issue (low/normal FSH).
4
Evaluate for central nervous system pathology via brain MRI.
Visualization of the hypothalamus, pituitary gland, and olfactory tracts.
Low FSH combined with anosmia strongly suggests Kallmann syndrome, but imaging must confirm olfactory bulb agenesis and definitively exclude structural sellar masses.
5
Treat the underlying estrogen deficiency.
Initiation of hormone replacement therapy.
Estrogen and progestin therapy is required for the development of secondary sexual characteristics and prevention of osteoporosis in patients with permanent hypogonadotropic hypogonadism.

Key Concept

The step-wise algorithmic evaluation of primary amenorrhea and the diagnosis of hypogonadotropic hypogonadism (Kallmann syndrome).
Rate this question